Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer
暂无分享,去创建一个
T. Watabe | J. Hatazawa | S. Mabuchi | Michiko Kodama | Kae Hashimoto | K. Sawada | Naoko Komura | Eriko Yokoi | Kotaro Shimura | Yuri Matsumoto | Mahiru Kawano | Tomoyuki Sasano | T. Kimura | Katsumi Kozasa | Kenjiro Sawada
[1] S. Mabuchi,et al. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer , 2020, Cancer Immunology, Immunotherapy.
[2] J. Hatazawa,et al. Pretreatment tumor-related leukocytosis misleads positron emission tomography-computed tomography during lymph node staging in gynecological malignancies , 2020, Nature Communications.
[3] S. Mabuchi,et al. The role of myeloid-derived suppressor cells in endometrial cancer displaying systemic inflammatory response: clinical and preclinical investigations , 2019, Oncoimmunology.
[4] S. Mabuchi,et al. Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models , 2019, Oncotarget.
[5] C. Haie-meder,et al. Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy , 2019, Oncoimmunology.
[6] E. Morii,et al. Prostaglandin E2 produced by myeloid-derived suppressive cells induces cancer stem cells in uterine cervical cancer , 2018, Oncotarget.
[7] S. Groshen,et al. Predictive Value of FDG PET/CT to Detect Lymph Node Metastases in Cervical Cancer , 2018, Clinical nuclear medicine.
[8] S. Woo,et al. Performance of pre-treatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography for detecting metastasis in ovarian cancer: a systematic review and meta-analysis , 2018, Journal of gynecologic oncology.
[9] S. Mabuchi,et al. Myeloid-derived suppressor cells and their role in gynecological malignancies , 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[10] E. Morii,et al. The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations , 2018, Clinical Cancer Research.
[11] S. Mabuchi,et al. Comparison of clinical utility between neutrophil count and neutrophil–lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review , 2018, International Journal of Clinical Oncology.
[12] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[13] S. Mabuchi,et al. The Significance of Pretreatment Thrombocytosis and Its Association With Neutrophilia in Patients With Surgically Treated Endometrial Cancer , 2017, International Journal of Gynecologic Cancer.
[14] Jeong Won Lee,et al. Prognostic Value of Fluorine-18 Fluorodeoxyglucose Uptake of Bone Marrow on Positron Emission Tomography/Computed Tomography for Prediction of Disease Progression in Cervical Cancer , 2017, International Journal of Gynecologic Cancer.
[15] H. Salvesen,et al. High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature , 2016, The Journal of Nuclear Medicine.
[16] E. Morii,et al. The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer , 2015, Scientific Reports.
[17] S. Mabuchi,et al. Prognostic significance of systemic neutrophil and leukocyte alterations in surgically treated endometrial cancer patients: a monoinstitutional study. , 2015, Gynecologic oncology.
[18] E. Morii,et al. Uterine cervical cancer displaying tumor-related leukocytosis: a distinct clinical entity with radioresistant feature. , 2014, Journal of the National Cancer Institute.
[19] D. Mutch,et al. Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer. , 2011, Gynecologic oncology.
[20] Y. Takeda,et al. Diagnostic value of FDG‐PET for lymph node metastasis and outcome of surgery for biliary cancer , 2011, Journal of surgical oncology.
[21] S. Kinomura,et al. A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity , 2009, Annals of nuclear medicine.
[22] J. Philippé,et al. FDG uptake by the bone marrow in NSCLC patients is related to TGF-β but not to VEGF or G-CSF serum levels , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[23] Hiroshi Watanabe,et al. Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT. , 2006, Nuclear medicine and biology.
[24] R. Wahl,et al. Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] H. Hamada,et al. Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. , 1998, Human gene therapy.
[26] R. Samulski,et al. Rescue of adeno-associated virus from recombinant plasmids: Gene correction within the terminal repeats of AAV , 1983, Cell.
[27] S. Mabuchi,et al. G-CSF induces focal intense bone marrow FDG uptake mimicking multiple bone metastases from uterine cervical cancer: a case report and review of the literature. , 2012, European journal of gynaecological oncology.
[28] K. Hongo,et al. A case report and review of the literature , 2006, Journal of Neuro-Oncology.
[29] R. Wahl,et al. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.